Skip to main content

MNK

Stock
—
—

Performance overview

MNK Price
Price Chart

Forward-looking statistics

Beta
—
Risk
—

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

—

Company info

Sector—
Industry—
Website—
Employees—
Market cap—

Fundamentals

Enterprise value$0.0
Revenue$0.0
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth—
Credit—
Liquidity—
Inflation—
Commodities—
Interest Rates—

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio—
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayAugust 6, 2019
Next dividend day—
Ex. dividend day—

News

Mallinckrodt Files For Chapter 11 Bankruptcy To Offload Opioid Fines

Drug manufacturer Mallinckrodt PLC (NYSE: MNK) disclosed Monday that it has voluntarily initiated Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court to restructure its operations and pare down debt. Mallinckrodt becomes the third major opioid maker to seek bankruptcy protection to offload liabilities related to the U.S. opioid epidemic, reports Bloomberg.

Benzinga (October 12, 2020)
Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall

Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.

Zacks Investment Research (September 15, 2020)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free